Abiomed Impella 2.5 Receives FDA Approval For Elective And Urgent High Risk Percutaneous Coronary Intervention (PCI) Procedures
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that it has received U.S.
Source: Medical Design Online News - Category: Medical Equipment Source Type: news
More News: Angioplasty | Cardiology | Coronary Angioplasty | Heart | Medical Devices | Percutaneous Coronary Intervention